Return on Assets (ROA): 13.21%
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 13.21% is 11% below its 5-year average of 14.86%, near the low end of its 5-year range (11.56%–19.97%).
As of Saturday, June 27, 2026. 5.34% above its 12-month average of 12.54%.
WST Return on Assets (ROA) Chart
Annual fiscal-year return on assets; no daily interpolation.
WST Average Return on Assets (ROA) Chart
WST Current vs Average Return on Assets (ROA) Chart
WST Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
13.21%
RETURN ON ASSETS (ROA) AVG TTM
12.54%
RETURN ON ASSETS (ROA) AVG 3Y
14.20%
RETURN ON ASSETS (ROA) AVG 5Y
14.86%
RETURN ON ASSETS (ROA) AVG 10Y
12.23%
RETURN ON ASSETS (ROA) AVG 15Y
10.28%
RETURN ON ASSETS (ROA) AVG 20Y
9.35%
CURRENT VS TTM AVG
+5.34%
CURRENT VS 3Y AVG
-6.94%
CURRENT VS 5Y AVG
-11.08%
CURRENT VS 10Y AVG
+8.01%
CURRENT VS 15Y AVG
+28.50%
CURRENT VS 20Y AVG
+41.28%
WST Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.79B | 13.21% | 12.54% | 14.20% | 14.86% |
| Waters Corporation (WAT)vs › | $24.41B | 1.83% | 13.34% | 15.53% | 17.15% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.54B | 23.85% | 25.02% | 24.63% | 23.85% |
| Quest Diagnostics Incorporated (DGX)vs › | $23.23B | 6.14% | 5.75% | 6.24% | 8.30% |
| BioNTech SE (BNTX)vs › | $23.07B | -6.03% | -3.96% | 9.16% | 17.06% |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 19.17% | 16.59% | 14.73% | 13.22% |
| Moderna, Inc. (MRNA)vs › | $26.69B | -27.80% | -24.02% | -10.32% | -0.33% |
| Incyte Corporation (INCY)vs › | $22.73B | 19.51% | 9.54% | 8.43% | 7.44% |
| DexCom, Inc. (DXCM)vs › | $27.07B | 14.03% | 11.04% | 9.26% | 8.83% |
| Labcorp Holdings Inc. (LH)vs › | $22.26B | 4.93% | 4.41% | 4.42% | 6.18% |
Asset Efficiency
ROA
13.2%
ROE
18.1%
Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for West Pharmaceutical Services, Inc. (WST)?
- The return on assets (ROA) for WST stock is 13.21%.
- Is West Pharmaceutical Services, Inc.'s return on assets (ROA) high or low?
- The return on assets (ROA) of 13.21% is 11% below its 5-year average of 14.86%, near the low end of its 5-year range (11.56%–19.97%).
- What is the TTM average return on assets (ROA) for West Pharmaceutical Services, Inc. (WST)?
- The TTM average return on assets (ROA) for WST stock is 12.54%.
- What is the 3Y average return on assets (ROA) for West Pharmaceutical Services, Inc. (WST)?
- The 3Y average return on assets (ROA) for WST stock is 14.20%.
- What is the 5Y average return on assets (ROA) for West Pharmaceutical Services, Inc. (WST)?
- The 5Y average return on assets (ROA) for WST stock is 14.86%.
- What is the 10Y average return on assets (ROA) for West Pharmaceutical Services, Inc. (WST)?
- The 10Y average return on assets (ROA) for WST stock is 12.23%.
- What is the 15Y average return on assets (ROA) for West Pharmaceutical Services, Inc. (WST)?
- The 15Y average return on assets (ROA) for WST stock is 10.28%.
- What is the 20Y average return on assets (ROA) for West Pharmaceutical Services, Inc. (WST)?
- The 20Y average return on assets (ROA) for WST stock is 9.35%.
WST Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 11.56% |
| 2024-12-31 | 13.52% |
| 2023-12-31 | 15.50% |
| 2022-12-31 | 16.20% |
| 2021-12-31 | 19.97% |
| 2020-12-31 | 12.39% |
| 2019-12-31 | 10.32% |
| 2018-12-31 | 12.99% |
| 2017-12-31 | 8.09% |
| 2016-12-31 | 8.36% |
| 2015-12-31 | 5.64% |
| 2014-12-31 | 7.61% |
| 2013-12-31 | 6.72% |
| 2012-12-31 | 5.16% |
| 2011-12-31 | 5.40% |
| 2010-12-31 | 5.05% |
| 2009-12-31 | 5.71% |
| 2008-12-31 | 7.36% |
| 2007-12-31 | 5.96% |
| 2006-12-31 | 7.31% |
| 2005-12-31 | 5.54% |
| 2004-12-31 | 2.95% |
| 2003-12-31 | 5.12% |
| 2002-12-31 | 3.43% |
| 2001-12-31 | -1.02% |
| 2000-12-31 | 0.29% |
| 1999-12-31 | 7.01% |
| 1998-12-31 | 1.33% |
| 1997-12-31 | 9.29% |
| 1996-12-31 | 3.44% |
Related Metrics
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green